Dr. Monk on Bevacizumab in Cervical Cancer

Bradley Monk, MD
Published Online: Tuesday, Dec 31, 2013
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Monk says the recently completed phase III GOG 240 study looked at the addition of bevacizumab to standard chemotherapy for the treatment of metastatic cervical cancer. The study showed that adding bevacizumab improved overall survival by nearly 4 months and improved response rate to about 50%.

Monk says this is a remarkable achievement, since metastatic cervical cancer is resistant to chemotherapy.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Monk says the recently completed phase III GOG 240 study looked at the addition of bevacizumab to standard chemotherapy for the treatment of metastatic cervical cancer. The study showed that adding bevacizumab improved overall survival by nearly 4 months and improved response rate to about 50%.

Monk says this is a remarkable achievement, since metastatic cervical cancer is resistant to chemotherapy.

Online CME Activities
TitleExpiration DateCME Credits
32nd Annual Miami Breast Cancer Conference® Community Practice ConnectionsMay 29, 20161.25
Community Practice Connections: 8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary MalignanciesMay 30, 20161.5